|Systematic (IUPAC) name|
|Trade names||Fucidin, Fucithalmic|
|Bioavailability||91% oral bioavailability|
|Protein binding||97 to 99%|
|Half-life||Approximately 5 to 6 hours in adults|
|ATC code||D06 D09 (dressing) J01 S01|
| (what is this?)
Fusidic acid is a bacteriostatic antibiotic that is often used topically in creams and eyedrops, but may also be given systemically as tablets or injections. The global problem of advancing antimicrobial resistance has led to a renewed interest in its use recently.
Fusidic acid acts as a bacterial protein synthesis inhibitor by preventing the turnover of elongation factor G (EF-G) from the ribosome. Fusidic acid is effective primarily on gram-positive bacteria such as Staphylococcus species, Streptococcus species,  and Corynebacterium species. Fusidic acid inhibits bacterial replication and does not kill the bacteria, and is therefore termed bacteriostatic.
Fusidic acid is a true antibiotic, derived from the fungus Fusidium coccineum and was developed by Leo Laboratories in Ballerup, Denmark and released for clinical use in the 1960s. It has also been isolated from Mucor ramannianus and Isaria kogana. The drug is licensed for use as its sodium salt sodium fusidate, and it is approved for use under prescription in South Korea, Japan, UK, Canada, Europe, Australia, New Zealand, Thailand, India and Taiwan. A different oral dosing regimen, based on the compound's Pharmacokinetic/pharmacodynamic (PK-PD) profile is in clinical development in the U.S. as Taksta.
Fusidic acid is active in vitro against Staphylococcus aureus, most coagulase-negative staphylococci, Beta-hemolytic streptococci, Corynebacterium species, and most clostridium species. Fusidic acid has no known useful activity against enterococci or most Gram-negative bacteria (except Neisseria, Moraxella, Legionella pneumophila, and Bacteroides fragilis). Fusidic acid is active in vitro and clinically against Mycobacterium leprae but has only marginal activity against Mycobacterium tuberculosis.
One important clinical use of fusidic acid is its activity against methicillin-resistant Staphylococcus aureus. Many strains of MRSA remain sensitive to fusidic acid, but, because there is a low genetic barrier to drug resistance (a single point mutation is all that is required), fusidic acid must never be used on its own to treat serious MRSA infection and should be combined with another antimicrobial such as rifampicin when administering oral or topical dosing regimens approved in Europe, Canada, and elsewhere. However, resistance selection is low when pathogens are challenged at high drug exposure. An orally-administered mono-therapy with a high loading dose is under development in the United States.
Topical fusidic acid is occasionally used as a treatment for acne vulgaris. As a treatment for acne, fusidic acid is often partially effective at improving acne symptoms. However, research studies have indicated that fusidic acid is not as highly active against Propionibacterium acnes as many other antibiotics that are commonly used as acne treatments. Fusidic acid is also found in several additional topical skin and eye preparations (e.g. Fucibet), although its use for these purposes is controversial.
Fusidic acid is being tested for indications beyond skin infections. There is evidence from compassionate use cases that fusidic acid may be effective in the treatment of patients with prosthetic joint-related chronic osteomyelitis.
Fusidic acid should not be used on its own to treat S. aureus infections when used at low drug dosages. However, it may be possible to use fusidic acid as monotherapy when used at higher doses. The use of topical preparations (skin creams and eye ointments) containing fusidic acid is strongly associated with the development of resistance, and there are voices agitating against the continued use of fusidic acid monotherapy in the community. Topical preparations used in Europe often contain fusidic acid and gentamicin in combination, which helps to prevent the development of resistance.
Depending on the reason for which sodium fusidate is prescribed, the adult dose can be 250 mg twice a day and or up to 750 mg three times a day. (Skin conditions normally need the smaller dose). It is available in tablet and suspension form. A front-loading oral dosing regimen[clarification needed] is in clinical development in the U.S. based on the pharmacokinetic/pharmacodynamic profile of the compound. It incorporates a dose of 1,500 mg twice on the first day followed by 600 mg twice-daily. It has been demonstrated in an in vitro model to have a low potential for selection of resistant organisms.
There is an intravenous preparation available, but it is irritant to veins, causing phlebitis. Most people absorb the drug extremely well after taking it orally, so, if a patient can swallow, there is not much need to administer it intravenously, even if used to treat endocarditis (infection of the heart chambers).
There is inadequate evidence of safety in human pregnancy. Animal studies and many years of clinical experience suggest that fusidic acid is devoid of teratogenic effects (birth defects), but fusidic acid can cross the placental barrier.Cite error: A
<ref> tag is missing the closing
</ref> (see the help page).
- Patients taking the drug should tell their doctors if they notice that their urine is 'very dark', if their feces are 'very pale', or if their skin or the whites of their eyes become yellow, the Australian data sheet for patients adds.
Because the drug is not licensed for use in the U.S., there are no Clinical and Laboratory Standards Institute standard definitions of fusidic acid resistance. However, in vitro susceptibility studies of U.S. strains of several bacterial species such as S. aureus, including MRSA and coagulase negative Staphylococcus, indicate potent activity against these pathogens
In the UK and Australia, susceptibility is defined as a minimum inhibitory concentration (MIC) of 0.25 mg/l or 0.5 mg/l or less. Resistance is defined as an MIC of 2 mg/l or more. In laboratories using disc diffusion methods, susceptibility for a 2.5 µg disc is defined as a zone of 22 mm or more, and resistance is defined as a zone of 17 mm or less; intermediate values are defined as intermediate resistance. These susceptibility criteria are based on lower dosing regimens used outside of the U.S. Clinical trials in the U.S. incorporate a different dosing regimen that results in higher blood levels. Therefore, the U.S. dosing regimen may warrant different susceptibility criteria.
Mechanisms of resistance have been extensively studied only in Staphylococcus aureus. The most important mechanism is the development of point mutations in fusA, the chromosomal gene that codes for EF-G. The mutation alters EF-G so that fusidic acid is no longer able to bind to it. Resistance is readily acquired when fusidic acid is used alone and commonly develops during the course of treatment. As with most other antibiotics, resistance to fusidic acid arises less frequently when used in combination with other drugs. For this reason, fusidic acid should not be used on its own to treat serious Staph. aureus infections. However, at least in Canadian hospitals, data collected between 1999-2005 showed rather low rate of resistance of MSSA and MRSA to fusidic acid, and mupirocin was found to be the more problematic topical antibiotic for the aforementioned conditions.
Some bacteria also mediate resistance via the fusB gene, which is carried on a plasmid; the mechanism by which fusB causes resistance is unknown.
Fusidic acid should not be used with quinolones, with which they are antagonistic. When combined with rifampicin, the action of fusidic acid is additive or synergistic.
It has been reported on August 8, 2008, that the Irish Medicines Board is investigating the death of a 59-year-old Irish man who developed rhabdomyolysis after combining Lipitor and Fusidic Acid, and three similar cases. In August, 2011, the UK's Medicines and Healthcare products Regulatory Agency issued a Drug Safety Update warning that "Systemic fusidic acid (Fucidin) should not be given with statins because of a risk of serious and potentially fatal rhabdomyolysis. "
Trade names and preparations
- Fucidin (of Leo in Canada and the US)
- Fucidin H (topical cream with corticosteroid - Leo)
- Fucidin (of Leo in UK/ Leo-Ranbaxy-Croslands in India)
- Fucidine (of Leo in France)
- Fucidin (of Leo in Norway)
- Fucidin (of Adcock Ingram, licenced from Leo, in South Africa)
- Fucithalmic (of Leo in the UK, the Netherlands, Denmark and Portugal)
- Fucicort (topical mixture with hydrocortisone)
- Fucibet (topical mixture with betamethasone)
- Ezaderm (topical mixture with betamethasone)(of United Pharmaceutical "UPM" in Jordan)
- Fuci (of pharopharm in Egypt)
- Fucizon (topical mixture with hydrocortisone of pharopharm in Egypt)
- Foban (topical cream in New Zealand)
- Betafusin (cream mixture with betamethasone valerate in Greece)
- Fusimax (of Schwartz in India)
- Fusiderm (topical cream and ointment by indi pharma in India)
- Fusid (in Nepal)
- Fudic (topical cream in India)
- Fucidin (후시딘, of Dong Wha Pharm in South Korea)
- Stanicid (in Serbia)
- Dermy (Topical cream of W.Woodwards in Pakistan)
- Fugen Cream (膚即淨軟膏 in Taiwan)
- Phudicin Cream (in China; 夫西地酸)
- Dermofucin cream ,ointment and gel (in Jordan)
- Optifucin viscous eye drops (of API in Jordan)
- Verutex (of Roche in Brazil)
- TAKSTA (of Cempra in U.S.)
- Futasole (of Julphar in Gulf and north Africa)
- Stanicid (2% ointment of Hemofarm in Serbia)
- Fuzidin (tablets of Biosintez in Russia)
- Fuzimet (ointment with methyluracil of Biosintez in Russia)
- Axcel Fusidic Acid(2% cream and ointment of Kotra Pharma, Malaysia)
- Falagas ME, Grammatikos AP, Michalopoulos A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther. 2008; 6(5):593-600 PMID 18847400
- Leclercq R, Bismuth, R, Casin, I, Cavallo, JD, Croize, J, Felten, A, Goldstein, F, Monteil, H, Quentin-Noury, C, Reverdy, M, Vergnaud, M, Roiron, R. (2000) In Vitro Activity of Fusidic Acid Against Streptococci isolated form Skin and Soft Tissue Infections. J. Antimicrob. Chemother. 45(1): 27-29.
- Moriarty SR, Clark K, Scott D, Degenhardt TP, Fernandes P, Craft JC, Corey GR, Still JG and Das A (2010). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract L1-1762
- Existing drug will cure hospital superbug MRSA, say scientists – The Guardian, 17 January 2007.Accessed 2008-01-17.
- O'Neill AJ and Chopra I (2004). Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Expert Opin. Investig. Drugs. 13(8):1045-1063
- Spelman. (1999). "Fusidic acid in skin and soft tissue infections.". International Journal of Antimicrobial Agents. PMID 10528787.
- "Fusidic Acid and Acne Vulgaris". ScienceOfAcne.com. 2011-09-11. Retrieved 2012-08-14.
- Sommer, et al. (1997). "Investigation of the mechanism of action of 2% fusidic acid lotion in the treatment of acne vulgaris.". Clinical Experimental Dermatology. PMID 9536540.
- Howden BP, Grayson ML (2006). "Dumb and dumber—the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus". Clin Infect Dis 42 (3): 394–400. doi:10.1086/499365. PMID 16392088.
- Wolfe, CR (2011) Case report: treatment of chronic osteomyelitis. Clinical Infectious Diseases 52(Supplement 7): S538-S541
- Mason BW, Howard AJ, Magee JT (2003). "Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing". J Antimicrob Chemother 51 (4): 300–3. doi:10.1093/jac/dkg190. PMID 12654748.
- Fucidin data sheet archived by New Zealand government. December 2005.Accessed: 2007-09-09.
- Castanheira M, Watters AA, Bell JM, Turnidge JD and Jones RN (2010). Fusidic acid resistance rates and prevalence of resistance mechanisms among 'Staphylococcus spp. isolated in North America and Australia, 2007-2008. Antimicrobial Agents and Chemotherapy 54:3614-3617.
- Pfaller M, Castaneira M, Sader H and Jones R (2010). Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. International Journal of Antimicrobial Agents 35:282-287.
- Castanheira M, Mendes RE, Rhomberg PR and Jones RN (2010). Activity of fusidic acid tested against contemporary Staphylococcus aureus collected from United States hospitals. Infectious Diseases Society of America, 48th Annual Meeting, Abstract 226.
- Turnidge J, Collignon P (1999). "Resistance to fusidic acid". Int J Antimicrob Agents 12 (Suppl 2): S35–44. doi:10.1016/S0924-8579(98)00072-7.
- Besier S, Ludwig A, Brade V, Wichelhaus TA (2003). "Molecular analysis of fusidic acid resistance in Staphylococcus aureus". Mol Microbiol 47 (2): 463–9. doi:10.1046/j.1365-2958.2003.03307.x. PMID 12519196.
- Rennie RP (2006). "Susceptibility of Staphylococcus aureus to fusidic acid:Canadian data". J Cutan Med Surg 10 (6): 277–280. PMID 17241597.
- Collignon P, Turnidge J (1999). "Fusidic acid in vitro activity". Int J Antimicrob 12 (Suppl 2): S45–58. doi:10.1016/S0924-8579(98)00073-9.
- Riegel, Ralph (2008-08-08). "Man died after rare medical reaction to cholesterol drug". Irish Independent.
- Drug Safety Update Sept 2011, vol 5 issue 2: A1.
|Wikimedia Commons has media related to Fusidic acid.|